European Archives - Page 442 of 1134 - European Medical Journal

Reflections and predictions for 2023

Explore the key trends and themes industry experts predict will be in store for pharma over the next 12 months.

Mental health matters in pharma's approach to care

Treatments for cancer are continuously advancing, but pharma must also focus on supporting patients’ mental health.

Attracting diverse talent into STEM

This infographic explores how the pharmaceutical industry is attracting and supporting the future STEM workforce with DE&I initiatives.

The Efficacy and Safety of SARS-CoV-2 Vaccinations in People with Multiple Sclerosis

While people with multiple sclerosis (MS) are not more likely to contract COVID-19, the incidences of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and COVID-19-related complications may be higher for people with MS who have comorbidities or who are taking certain disease modifying therapies (DMT).

EMJ Neurology 11 [Supplement 1] 2023

While people with multiple sclerosis (MS) are not more likely to contract COVID-19, the incidences of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and COVID-19-related complications may be higher for people with MS who have comorbidities or who are taking certain disease modifying therapies (DMT).

Newer Oral Levothyroxine Formulations: Is It Time to Switch Over?

Primary hypothyroidism is a frequent presentation in primary care, and is treated with levothyroxine sodium tablets once daily in the morning in the fasting state.

EMJ

Key insights from ECCO 2023 - An interdisciplinary expert roundtable discussion | 14th March 2023 4 PM GMT

Join us for an interdisciplinary expert roundtable discussion to gain a deeper understanding of emerging data from ECCO 2023 and real-world evidence with biosimilars.

The 2023 pharma forecast

Join Helena and Isabel in ringing in the 2023 with a special predictions episode. What’s in store for pharma this year?

Urology

Urinary Bladder Stone: A Late Complication of Bulking Injection

Polyacrylamide hydrogel (PAHG) Bulkamid® (Axonics, Irvine, California, USA) was introduced in Europe as a promising periurethral bulking agent for the treatment of female stress and mixed urinary incontinence in 2006.

Improving Compliance, Improving Results

Steven Feldman joins Jonathan Sackier to discuss psoriasis management, patient compliance, and patient satisfaction